Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates
9 octobre 2017
Madison, Wisc. Castres, France (October 9, 2017) -Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces, together with leading French pharmaceutical company Pierre Fabre, the extension of its ongoing collaboration to develop new phospholipid drug conjugates™ (PDCs™).
Following the review of the encouraging preclinical data generated by these PDC compounds across multiple solid tumor types, the parties have decided to extend the collaboration. The aim of the extension is to allow further evaluation of the synergistic effects of the phospholipid ether when combined with Pierre Fabre’s cytotoxic payloads. The program teams will continue to explore these new PDC compounds in order to expedite the development of these novel targeted chemotherapeutics towards essential medicines. The research collaboration was entered into with the original objective to co-design a small library of PDCs to achieve in-vivo proof-of-concept for these newly constructed compounds.
The extension of the existing research agreement with Pierre Fabre is a tribute to the success of our collaboration to date and the promise of our next generation delivery technology. The PDC molecules have demonstrated a clear cancer targeting advantage over the unconjugated payloads,” said Jim Caruso, president and CEO of Cellectar Biosciences. “We look forward to leveraging the synergistic technologies and skills of our respective organizations to further advance this exciting research.
About Phospholipid Drug Conjugates™ (PDCs™)
Cellectar’s product candidates are built upon its patented cancer cell-targeting delivery and retention platform of optimized phospholipid ether-drug conjugates™ (PDCs™). The company designed its phospholipid ether (PLE) carrier platform to be coupled with a variety of payloads to facilitate the discovery and development of improved targeted novel therapeutic compounds. The basis for selective tumor targeting of our PDC compounds lies in the differences between the plasma membranes of cancer cells compared to those of normal cells. Cancer cell membranes are highly enriched in lipid rafts, which are glycolipoprotein microdomains of the plasma membrane of cells that contain high concentrations of cholesterol and sphingolipids, and serve to organize cell surface and intracellular signaling molecules. PDCs™ have been tested in more than 80 different xenograft models of cancer.
Press Contact :
Valérie Roucoules - 01 49 10 83 84